| abstract |
Methods are provided for clinical treatment of neuromyelitis optica spectrum disorders (NMOSD) using anti-C5 antibodies or antigen-binding fragments thereof. The present disclosure provides methods of treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof by administering an antibody that specifically binds complement component 5 (C5). In certain embodiments, antibodies that specifically bind C5 reduce the rate at which C5 is cleaved into C5a and C5b in vivo. In other embodiments, antibodies that specifically bind C5 bind one or both of the C5a and/or C5b fragments. In any of these embodiments, antibodies that specifically bind C5 reduce the complement cascade at C5, thereby reducing the release of proinflammatory mediators and the formation of cytolytic pores. |